1. Home
  2. LQDA vs RDNT Comparison

LQDA vs RDNT Comparison

Compare LQDA & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$68.52

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo RadNet Inc.

RDNT

RadNet Inc.

HOLD

Current Price

$73.96

Market Cap

4.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
RDNT
Founded
2004
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.8B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
LQDA
RDNT
Price
$68.52
$73.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$41.00
$82.80
AVG Volume (30 Days)
1.5M
633.7K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
51.81
N/A
EPS
1.26
N/A
Revenue
$158,320,000.00
$1,616,630,000.00
Revenue This Year
$278.87
$22.78
Revenue Next Year
$57.13
$10.70
P/E Ratio
$54.56
N/A
Revenue Growth
1031.18
13.05
52 Week Low
$21.15
$50.82
52 Week High
$93.61
$85.84

Technical Indicators

Market Signals
Indicator
LQDA
RDNT
Relative Strength Index (RSI) 40.05 52.91
Support Level $30.48 $73.73
Resistance Level $92.35 $74.55
Average True Range (ATR) 3.20 2.43
MACD -0.54 -0.66
Stochastic Oscillator 22.32 9.63

Price Performance

Historical Comparison
LQDA
RDNT

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.

Share on Social Networks: